perspective, the next step would be to use the above antibodies as frontline therapy, in combination with standard chemotherapy. As a consequence, some concern could be raised about re-administration of such antibodies at the time of relapse because of the possible risk of the downregulation of their expression at the surface of the leukaemic cells. Indeed, loss of CD20 expression after rituximab is now a well-known phenomenon and interpreted as a mechanism of drug resistance in patients with CD20 þ lymphoma. 2 However, other studies using the anti-CD33, anti-CD52 or anti-CD22 therapeutic antibodies did not show that downregulation of these sAg is likely to be a common leukaemia-resistance pathway, 3, 7, 8 suggesting that they can be used both at the time of diagnosis and relapse in B-ALL.
Our series also suggest that a combination of therapeutic antibodies (with or without chemotherapy) could be envisioned in a majority of patients, at least from a theoretical point of view. The latter proved to be feasible in chronic lymphocytic leukaemia, where the combination of rituximab and Campath has shown efficacy without excessive toxicity. 7 Thus, from our results, therapeutic associations combining anti-CD22/anti-CD52, anti-CD22/anti-CD33 or anti-CD33/anti-CD52 may represent attractive candidates for prospective testing in phase 1-2 trials including refractory B-ALL patients. We have evaluated whether targeting the Src family kinase (SFK) cascade, an early component of B-cell receptor (BCR) signaling, is an effective strategy to treat AIDS-related lymphoma (ARL). The incidence of non-Hodgkin's lymphomas (NHLs) is estimated to be between 4 and 10% in HIV þ individuals, although the frequency of at least some subsets appears to be decreasing with combination antiretroviral therapy. The incidence of Hodgkin's lymphoma (HL) is also increased in HIV-infected individuals, but it is not considered to be an AIDS-defining condition. The pathogenesis of lymphoma in the context of AIDS is complex and thought to be related to disrupted immune surveillance, chronic antigenic stimulation, genetic alterations, cytokine dysregulation and herpesvirus infection. Although HIV-related lymphomas are almost always of B-cell origin, they are morphologically diverse. Several subtypes are similar to lymphomas occurring in immunocompetent patients, whereas others preferentially develop in the context of AIDS. HIV-related lymphomas can be classified by morphology and immunophenotyping (as in the classification of World Health Organization), and/or by primary site of presentation (that is, systemic, primary central nervous system and body cavity). The World Health Orgnization classification divides ARL into Burkitt lymphomas; diffuse large B-cell lymphomas (DLBCL) that can be sometimes separated into centroblastic and immunoblastic categories; HL; primary effusion lymphomas (PELs), plasmablastic lymphomas (oral cavity or associated with multicentric Castleman's disease), polymorphic BCLs and primary central nervous system lymphomas.
1 Viral associations are particularly common in ARL. Epstein-Barr virus (EBV) is present in most primary central , and approximately 90% of cases are also coinfected by EBV. Src family kinases (SFKs) are activated after ligation of the B cell receptor (BCR), and they phosphorylate downstream signaling proteins in tyrosine residues relaying B-cell signaling cascades that lead to B-cell activation and proliferation. These kinases play an important role in lymphoma pathogenesis. 2 We have shown in a companion study that Src kinases are constitutively active in DLBCL cells in immunocompetent individuals, and inhibition of these kinases using dasatinib inhibits proliferation of the lymphoma cells. 3 We postulated that targeting Src tyrosine kinases pharmacologically would also inhibit the survival and growth of the ARL cells.
Control No stimulation Stimulation
Ly7-p-PLCγ 2 Ly7-p-PLCγ 2 We tested the effect of dasatinib in 11 ARL cell lines, including six PELs, three EBV þ DLBCL (immunoblastic) lymphomas, one EBV À DLBCL and one EBV þ Burkitt lymphoma (Table 1) . Cell proliferation and viability in the presence of increasing doses of dasatinib were determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) assay. In contrast to DLBCL in HIV À individuals, most of which show sensitivity to dasatinib in the nanomolar range, none of the ARL cell lines tested showed sensitivity at doses as high as 1 mM. One EBV þ HL cell line was also evaluated, and found to be resistant to dasatinib treatment. Results are shown in Table 1 . Concentrations higher than 150 nM cannot be achieved in patients without significant toxic effects, so concentrations higher than 1 mM were not tested.
Non-AIDS DLBCLs have the activation of SFKs. The activity of SFK including Src, Lyn, Hck and Blk are invariably inhibited in both sensitive and resistant DLBCL cell lines, whereas the activity of two downstream signaling molecules, Syk and PLCg2, are inhibited by dasatinib only in sensitive cell lines. 3 To determine the molecular events that occur in ARL after dasatinib treatment in comparison to non-AIDS DLBCL, we performed immunoblot analyses for total tyrosine phosphorylation in the absence or presence of increasing doses of dasatinib (Figure 1 ). Both PEL (KSHV þ ) cell lines evaluated (BC2 and VG-1) revealed very low basal levels of total phosphotyrosine, which did not change upon treatment with dasatinib. In contrast, the EBVassociated (LCL-JP06 and BCKN-1) and the virus-negative ARL cell line (BCHNÀ1) had significantly higher basal tyrosine kinase activity. The HL cell line, L591, has lower but detectable level of phosphotyrosines. In these non-PEL cell lines, dasatinib was able to inhibit tyrosine phosphorylation at doses between 10-50 nM. We further evaluated the phosphorylation status of two SFKs, Src and Lyn. In cell lines that had total tyrosine phosphorylation, basal phosphorylation of Src and Lyn was detected, and their activities were efficiently inhibited by treatment with dasatinib.
We next investigated the phosphorylation of Syk and PLCg2 by intracellular phosphospecific flow cytometry. The non-AIDS DLBCL cell line, LY7, was used as a dasatinib-responsive positive control. In this cell line, there was basal p-Syk and p-PLCg2. Upon BCR ligation with anti-Ig (immunoglobulin) M/IgG, levels of p-Syk and p-PLCg2 increase as evidenced by a right shift in the phospho-peaks (Figure 2 , line 1, left two panels). In the stimulated cells, dasatinib treatment led to a decrease in the phosphorylation of both p-Syk and p-PLCg2 (Figure 2 , line1, right two panels), indicating that the activities of the two signaling molecules are inhibited. When we examined ARL cell lines, in those that have little phosphotyrosines, including the PEL cell lines (BC2 and VG-1) and the HL cell line L591, cells did not respond to either IgM/IgG stimulation or dasatinib treatment (line 2-4). In the DLBCL cell line, BCHN-1, p-Syk and p-PLCg2 responded to BCR stimulation and dasatinib treatment in a similar fashion to LY7. However, in spite of this molecular response, this cell line did not respond to the inhibitor at cellular level as no inhibition in proliferation or viability was detected.
Our results indicate that in ARLs, inhibition of BCR signaling is not detrimental to cellular survival or proliferation. Lack of inhibition by dasatinib was unexpected and was in marked contrast to observations made in DLBCL occurring in immunocompetent individuals. 3 These findings have therapeutic as well as pathobiological implications. From the therapeutic standpoint, although dasatinib is likely to be beneficial in lymphoma patients without HIV infection, this approach is unlikely to be successful in patients with AIDS.
Although none of the 11 ARL cell lines tested showed any detrimental cellular responses to dasatinib at concentrations as high as 1 mM, two different mechanisms appear to account for this resistance. First, BCR signaling, as assessed by phosphorylation of Src, Lyn, Syk and PLCg2, is low in both PEL cell lines studied (BC2 and VG-1). This lymphoma subtype is characterized by the lack of expression of surface immunoglobulins, which would be consistent with a lack of signals stemming from the BCR. Although KSHV and EBV encode proteins that can activate SFKs (such as EBV LMP2A, KSHV K1 and K15), these viral proteins are not expressed in PEL. 4, 5 The second scenario was found in other ARL cell lines, which have high basal BCR signaling that was sensitive to dasatinib inhibition. However, in these cells BCR signaling is not essential, as inhibition by dasatinib did not affect their proliferation or survival. These results suggest that viral proteins may provide survival and proliferation signals through interaction with cellular proteins that are further downstream from these early events of BCR signaling. The precise mechanism in such cell lines will require further investigation. Regardless of the mechanism responsible for resistance to dasatinib, our findings indicate that ARLs have alternative signaling cascades that drive cellular proliferation and survival in the absence of BCR signaling.
